Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy
Julia Ruark, Erin Mullane, Nancy Cleary, et al.
Biology of Blood and Marrow Transplantation (2019) Vol. 26, Iss. 1, pp. 34-43
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela V. Maus, S. Alexander, Michael R. Bishop, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e001511-e001511
Open Access | Times Cited: 209
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao, Shengkang Huang, Sifei Chen, et al.
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 152
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
Ben Fleming, Paul Edison, Laura Kenny
BMJ (2023), pp. e071726-e071726
Closed Access | Times Cited: 40
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies
Craig W. Freyer, David L. Porter
Journal of Allergy and Clinical Immunology (2020) Vol. 146, Iss. 5, pp. 940-948
Open Access | Times Cited: 127
Value and affordability of CAR T-cell therapy in the United States
Salvatore Fiorenza, David Ritchie, Scott D. Ramsey, et al.
Bone Marrow Transplantation (2020) Vol. 55, Iss. 9, pp. 1706-1715
Closed Access | Times Cited: 104
Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations From the Cancer Neuroscience Initiative Working Group
Ashley M. Henneghan, Kathleen Van Dyk, Tara Kaufmann, et al.
JNCI Journal of the National Cancer Institute (2021) Vol. 113, Iss. 12, pp. 1625-1633
Open Access | Times Cited: 76
Microglia in Cancer Therapy-Related Cognitive Impairment
Erin M. Gibson, Michelle Monje
Trends in Neurosciences (2021) Vol. 44, Iss. 6, pp. 441-451
Open Access | Times Cited: 75
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review
Shakira J. Grant, Alyssa Grimshaw, Juliet Silberstein, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 6, pp. 294-302
Open Access | Times Cited: 63
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?
Sanne B. Schagen, Andrey S. Tsvetkov, Annette Compter, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 3, pp. 173-185
Closed Access | Times Cited: 62
The EBMT/EHA CAR-T Cell Handbook
Nicolaus Krogër, John G. Gribben, Christian Chabannon, et al.
Springer eBooks (2022)
Closed Access | Times Cited: 54
Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant
Surbhi Sidana, Amylou C. Dueck, Gita Thanarajasingam, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 8, pp. 473-482
Open Access | Times Cited: 44
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Mahmoud Elsawy, Julio C. Chávez, Irit Avivi, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2248-2260
Open Access | Times Cited: 43
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Jason R. Westin, Frederick L. Locke, Michael Dickinson, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 10, pp. 1894-1905
Open Access | Times Cited: 28
Cancer related cognitive impairment: a downside of cancer treatment
Kimberly Demos-Davies, Jessica Lawrence, Davis Seelig
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 10
Beyond the storm — subacute toxicities and late effects in children receiving CAR T cells
Haneen Shalabi, Juliane Gust, Agne Taraseviciute, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 6, pp. 363-378
Open Access | Times Cited: 54
Critical care management of chimeric antigen receptor T‐cell therapy recipients
Alexander Shimabukuro‐Vornhagen, Boris Böll, Peter Schellongowski, et al.
CA A Cancer Journal for Clinicians (2021) Vol. 72, Iss. 1, pp. 78-93
Open Access | Times Cited: 51
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
Michel Delforge, Nina Shah, Jesús F. San Miguel, et al.
Blood Advances (2021) Vol. 6, Iss. 4, pp. 1309-1318
Open Access | Times Cited: 49
Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies
Xin Shelley Wang, Samer A. Srour, Meagan Whisenant, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 11, pp. 930.e1-930.e10
Open Access | Times Cited: 46
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Dristhi Ragoonanan, Sajad Khazal, Hisham Abdel‐Azim, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 7, pp. 435-453
Open Access | Times Cited: 43
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Wen Lei, Mixue Xie, Qi Jiang, et al.
Cancers (2021) Vol. 13, Iss. 15, pp. 3912-3912
Open Access | Times Cited: 41
Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force
Geoff D.E. Cuvelier, Michelle Long Schoettler, Nataliya P. Buxbaum, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 8, pp. 426-445
Open Access | Times Cited: 34
Prolonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphoma treated with chimeric antigen receptor-modified T cell therapy
Luke Maillie, Sunita D. Nasta, Jakub Svoboda, et al.
Transplantation and Cellular Therapy (2025)
Closed Access
Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies
Rajshekhar Chakraborty, Brian T. Hill, Aneela Majeed, et al.
Transplantation and Cellular Therapy (2020) Vol. 27, Iss. 3, pp. 222-229
Open Access | Times Cited: 42
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments
Praveen Ramakrishnan Geethakumari, Dheepthi P. Ramasamy, Bhagirathbhai Dholaria, et al.
Current Hematologic Malignancy Reports (2021) Vol. 16, Iss. 4, pp. 345-356
Open Access | Times Cited: 38
Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study
Didier Maillet, Cathérine Belin, Christine Moroni, et al.
Neuro-Oncology (2021) Vol. 23, Iss. 9, pp. 1569-1575
Open Access | Times Cited: 35
Page 1 - Next Page

Scroll to top